((Automated translation by Reuters, please see disclaimer https://bit.ly/rtrsauto))
January 29 – **Shares of Science 37 SNCE.O, a clinical trial services provider, rise 20.5% to $5.71
**The company will be acquired by the telehealth and diagnostics company eMed
**eMed, through its unit, will purchase SNCE in a transaction valued at approximately $38 million for $5.75 per share in cash, representing a 21.3% premium over at the last closing of SNCE
**Both parties expect the transaction to be completed during the first quarter of 2024
**eMed provides at-home testing kits and has technology that helps streamline the process of enrolling patients into clinical trials, called Test-to-Treat
**SNCE believes eMed’s Test-to-Treat technology will help improve the company’s ability to access and enroll patients in studies more quickly
**The stock has fallen 52% in the last 12 months